Research location
Erlangen
Bavaria, Germany
Advertisement
Research activity in Erlangen
Bavaria, GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 108 trials and 108 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Erlangen
108 linked trials · page 1 of 3Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support PersonsNCT07788729 · 2026-04-21 · 1 site observation
RECRUITING
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)NCT07361497 · 2026-03-16 · 1 site observation
RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)NCT07282574 · 2026-03-10 · 1 site observation
RECRUITING
Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast CancerNCT07531693 · 2026-02-19 · 1 site observation
RECRUITING
OCTA in Cardiovascular Disease and Healthy ControlsNCT07359664 · 2025-12-01 · 1 site observation
RECRUITING
Immune Biomarkers in Prostate Cancer Patients Treated With BrachytherapyNCT07131956 · 2025-12-01 · 1 site observation
RECRUITING
Evaluating the Effectiveness of Typology-based Coaching on Patients' Therapy ManagementNCT07708571 · 2025-11-04 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.NCT07062965 · 2025-08-05 · 1 site observation
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30 · 1 site observation
RECRUITING
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)NCT06916507 · 2025-05-05 · 1 site observation
RECRUITING
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)NCT06841354 · 2025-03-16 · 1 site observation
RECRUITING
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceNCT06830720 · 2025-02-20 · 1 site observation
RECRUITING
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 1 site observation
RECRUITING
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)NCT06393374 · 2024-06-24 · 1 site observation
RECRUITING
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)NCT06312176 · 2024-04-14 · 1 site observation
RECRUITING
Effect of Renal Denervation on Bood Pressure in Patients on HemodialysisNCT06556407 · 2024-03-04 · 1 site observation
RECRUITING
PROCARE - PROstate Cancer Real World Evidence RegistryNCT06835218 · 2024-01-29 · 1 site observation
RECRUITING
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLCNCT06223711 · 2023-10-06 · 1 site observation
RECRUITING
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)NCT05332561 · 2023-06-29 · 1 site observation
RECRUITING
Effects of Intermittent Fasting and Exercise on Inflammation, Metabolism, and the Microbiome in Metabolic SyndromeNCT06885255 · 2023-06-01 · 1 site observation
RECRUITING
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)NCT05714085 · 2023-05-31 · 1 site observation
RECRUITING
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer PatientsNCT05452213 · 2022-10-12 · 1 site observation
RECRUITING
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)NCT05489705 · 2022-08-16 · 1 site observation
RECRUITING
German Dementia RegistryNCT07433010 · 2022-05-16 · 1 site observation
RECRUITING
Praegnant Breast Cancer: Early/Advanced/MetastaticNCT02338167 · 2014-06-01 · 1 site observation
RECRUITING
IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCENCT07521202 · 2026-10-01 · 1 site observation
NOT_YET_RECRUITING
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseNCT07170150 · 2025-11-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Dance Movement Therapy for Radio-oncological PatientsNCT07001033 · 2025-02-22 · 1 site observation
COMPLETED
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseNCT06760637 · 2025-01-06 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)NCT06018337 · 2024-01-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Effects of the Kata® Inhalations-App on Inhaler Handling Errors, Adherence, and Asthma Control in Patients With Asthma.NCT06178341 · 2023-12-20 · 1 site observation
COMPLETED
Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HDNCT06093334 · 2023-10-17 · 1 site observation
COMPLETED
TaKeTiNa in the Treatment of Depression: a Pilot Study.NCT05778643 · 2023-03-01 · 1 site observation
UNKNOWN
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)NCT05665595 · 2023-01-19 · 1 site observation
TERMINATED
Post Market Clinical Follow-up Study for the Pamira ICD Lead FamilyNCT05621187 · 2022-11-30 · 1 site observation
COMPLETED
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDONCT05033756 · 2022-07-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).NCT05116189 · 2021-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerNCT04975308 · 2021-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)NCT05036005 · 2021-07-11 · 1 site observation
UNKNOWN
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)NCT04895358 · 2021-06-18 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of LY3484356 in Women With Breast Cancer Before Having SurgeryNCT04647487 · 2021-04-21 · 1 site observation
COMPLETED
Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast CancerNCT05033769 · 2021-03-11 · 1 site observation
UNKNOWN
Sacituzumab Govitecan in Primary HER2-negative Breast CancerNCT04595565 · 2020-10-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)NCT04191135 · 2019-12-19 · 1 site observation
TERMINATED
TOLERA: Tolerance Enhancement in RANCT04120831 · 2019-10-07 · 1 site observation
UNKNOWN
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)NCT03924869 · 2019-06-25 · 1 site observation
TERMINATED
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)NCT03924856 · 2019-06-13 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)NCT03834519 · 2019-05-02 · 1 site observation
COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)NCT03820986 · 2019-03-12 · 1 site observation
COMPLETED
Facilitating Motor Skill Learning in Parkinson's Disease II (FaST-PD II)NCT03886090 · 2019-01-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.